Benzamide

Benzamide

SCHEMBL6786179

CCCCN(CCCC)c1ccc(C=C2SC(=S)N(CCS(=O)(=O)O)C2=O)cc1.NC(=O)c1ccccc1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PAX8 Q06710 1/20 0.47
▸ CISD1 Q9NZ45 2/20 0.46
▸ MAOA P21397 1/20 0.46
▸ POLB P06746 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ PTPN12 Q05209 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ PTPN7 P35236 1/20 0.44
▸ GPR35 Q9HC97 1/20 0.44
▸ PTPN22 Q9Y2R2 1/20 0.44
▸ AKR1B1 P15121 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzamide SCHEMBL6798464 0.98 PAX8 (0.47) PAX8CISD1MAOAPOLBNPSR1
SCHEMBL6788439 0.92 FFAR1 (0.50) PAX8MAOAPOLBKMT2APTPN12
SCHEMBL6789683 0.90 FFAR1 (0.49) PAX8MAOAPOLBKMT2APTPN12
SCHEMBL6786181 0.85 PAX8 (0.47) PAX8CISD1MAOAPOLBNPSR1
SCHEMBL6786169 0.85 PAX8 (0.47) PAX8CISD1MAOAPOLBNPSR1
SCHEMBL6798466 0.83 PAX8 (0.47) PAX8CISD1MAOAPOLBNPSR1
SCHEMBL6798462 0.83 PAX8 (0.47) PAX8CISD1MAOAPOLBNPSR1
SCHEMBL6795746 0.82 FFAR1 (0.48) PAX8MAOAPOLBKMT2AMEN1
SCHEMBL7490259 0.81 CISD1 (0.65) CISD1MAOAKMT2AMEN1AKR1B1
SCHEMBL7490262 0.81 CISD1 (0.65) CISD1MAOAKMT2AMEN1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 PAX8 4275/4885CISD1 993/4885MAOA 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback